These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482 [TBL] [Abstract][Full Text] [Related]
9. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients. Ashida A; Sakaizawa K; Uhara H; Okuyama R Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063 [TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study. Forschner A; Weißgraeber S; Hadaschik D; Schulze M; Kopp M; Kelkenberg S; Sinnberg T; Garbe C; Biskup S; Battke F Onco Targets Ther; 2020; 13():5017-5032. PubMed ID: 32581559 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance of BRAF Tang H; Kong Y; Si L; Cui C; Sheng X; Chi Z; Dai J; Yu S; Ma M; Wu X; Yu J; Xu T; Yu H; Yan J; Guo J Oncol Lett; 2018 Feb; 15(2):1839-1844. PubMed ID: 29434880 [TBL] [Abstract][Full Text] [Related]
13. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients. Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992 [TBL] [Abstract][Full Text] [Related]
14. Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic Herbreteau G; Vallée A; Knol AC; Théoleyre S; Quéreux G; Frénard C; Varey E; Hofman P; Khammari A; Dréno B; Denis MG Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664549 [TBL] [Abstract][Full Text] [Related]
15. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy. Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817 [TBL] [Abstract][Full Text] [Related]
16. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report. Calapre L; Warburton L; Millward M; Gray ES BMC Cancer; 2019 Nov; 19(1):1109. PubMed ID: 31727009 [TBL] [Abstract][Full Text] [Related]
18. Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy. Fitzgerald S; Blenkiron C; Stephens R; Mathy JA; Somers-Edgar T; Rolfe G; Martin R; Jackson C; Eccles M; Robb T; Rodger E; Lawrence B; Guilford P; Lasham A; Print CG Mol Diagn Ther; 2023 Jul; 27(4):537-550. PubMed ID: 37099071 [TBL] [Abstract][Full Text] [Related]
19. The dynamics of circulating tumour DNA (ctDNA) during treatment reflects tumour response in advanced melanoma patients. Di Nardo L; Del Regno L; Di Stefani A; Mannino M; Fossati B; Catapano S; Quattrini L; Pellegrini C; Cortellini A; Parisi A; Capoluongo E; Autilio C; Fargnoli MC; Peris K Exp Dermatol; 2023 Oct; 32(10):1785-1793. PubMed ID: 37533342 [TBL] [Abstract][Full Text] [Related]
20. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Chang GA; Tadepalli JS; Shao Y; Zhang Y; Weiss S; Robinson E; Spittle C; Furtado M; Shelton DN; Karlin-Neumann G; Pavlick A; Osman I; Polsky D Mol Oncol; 2016 Jan; 10(1):157-65. PubMed ID: 26440707 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]